IN2012DN00858A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00858A
IN2012DN00858A IN858DEN2012A IN2012DN00858A IN 2012DN00858 A IN2012DN00858 A IN 2012DN00858A IN 858DEN2012 A IN858DEN2012 A IN 858DEN2012A IN 2012DN00858 A IN2012DN00858 A IN 2012DN00858A
Authority
IN
India
Prior art keywords
propionamide
thiazol
pyrrolidin
methylamino
benzoyl
Prior art date
Application number
Other languages
English (en)
Inventor
Jeewan Thakur
Dong Yang
Lili Feng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN00858A publication Critical patent/IN2012DN00858A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN858DEN2012 2009-08-12 2010-08-11 IN2012DN00858A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12
PCT/EP2010/061679 WO2011018474A1 (en) 2009-08-12 2010-08-11 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

Publications (1)

Publication Number Publication Date
IN2012DN00858A true IN2012DN00858A (de) 2015-07-10

Family

ID=42937834

Family Applications (1)

Application Number Title Priority Date Filing Date
IN858DEN2012 IN2012DN00858A (de) 2009-08-12 2010-08-11

Country Status (24)

Country Link
US (4) US8623385B2 (de)
EP (1) EP2464644A1 (de)
JP (3) JP2013501751A (de)
KR (2) KR20120048008A (de)
CN (2) CN102471331B (de)
AR (1) AR077869A1 (de)
AU (4) AU2010283748A1 (de)
BR (1) BR112012003118A2 (de)
CA (1) CA2769616A1 (de)
CL (1) CL2012000349A1 (de)
CO (1) CO6612189A2 (de)
IL (1) IL217760A0 (de)
IN (1) IN2012DN00858A (de)
MA (1) MA33511B1 (de)
MX (2) MX351274B (de)
MY (1) MY160475A (de)
PE (2) PE20121132A1 (de)
PH (1) PH12014501890A1 (de)
RU (1) RU2671196C1 (de)
SG (1) SG177713A1 (de)
TN (1) TN2012000026A1 (de)
TW (1) TWI607006B (de)
WO (1) WO2011018474A1 (de)
ZA (1) ZA201200390B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020792A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118078A1 (en) 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
BR0312408A (pt) 2002-07-02 2005-04-19 Novartis Ag Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap)
AR048927A1 (es) * 2004-04-07 2006-06-14 Novartis Ag Compuestos heterociclicos como inhibidores de proteinas de apoptosis (iap); composiciones farmaceuticas que los contienen y su uso en el tratamiento de una enfermedad proliferativa
NZ589670A (en) * 2004-12-20 2013-01-25 Genentech Inc Pyrrolidine inhibitors of iap
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
US20120128742A1 (en) 2012-05-24
JP2016179976A (ja) 2016-10-13
AR077869A1 (es) 2011-09-28
JP2013501751A (ja) 2013-01-17
TW201118091A (en) 2011-06-01
KR20120048008A (ko) 2012-05-14
CA2769616A1 (en) 2011-02-17
JP2018172403A (ja) 2018-11-08
US20180370960A1 (en) 2018-12-27
WO2011018474A1 (en) 2011-02-17
ZA201200390B (en) 2012-10-31
SG177713A1 (en) 2012-02-28
MY160475A (en) 2017-03-15
CN105646471A (zh) 2016-06-08
PH12014501890B1 (en) 2015-09-14
MA33511B1 (fr) 2012-08-01
PE20170777A1 (es) 2017-07-04
BR112012003118A2 (pt) 2016-02-23
AU2010283748A1 (en) 2012-02-09
PE20121132A1 (es) 2012-09-04
TWI607006B (zh) 2017-12-01
AU2017254950B2 (en) 2018-09-20
US20140093570A1 (en) 2014-04-03
US8623385B2 (en) 2014-01-07
WO2011018474A8 (en) 2011-09-22
RU2012108931A (ru) 2013-09-27
CN102471331B (zh) 2016-01-13
AU2016203145A1 (en) 2016-06-02
TN2012000026A1 (en) 2013-09-19
MX351274B (es) 2017-10-06
CN102471331A (zh) 2012-05-23
US10093665B2 (en) 2018-10-09
AU2017254950A1 (en) 2017-11-23
CL2012000349A1 (es) 2012-09-07
US9540363B2 (en) 2017-01-10
AU2014213533A1 (en) 2014-09-04
KR20180020315A (ko) 2018-02-27
PH12014501890A1 (en) 2015-09-14
RU2671196C1 (ru) 2018-10-30
EP2464644A1 (de) 2012-06-20
US20170081319A1 (en) 2017-03-23
MX2012001844A (es) 2012-02-29
IL217760A0 (en) 2012-03-29
CO6612189A2 (es) 2013-02-01

Similar Documents

Publication Publication Date Title
IL236883A0 (en) Intermediate compounds for the preparation of (1-(s))-n-(s-cyclohexyl-2-{(4)-2-(s-(fluoro-benzoyl)-thiazol-2-yl]pyrrolidine-1-yl}-2 -oxo-ethyl)-2-methylamino-propionamide
EP2477625A4 (de) Pharmazeutische zusammensetzungen und formulierungen mit hemmern der pleckstrin-homologie-domäne und verwendungsverfahren dafür
UA105911C2 (uk) Сульфонамідні похідні
MX2010003866A (es) Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
MX2011003473A (es) Composiciones para el cuidado bucal.
TR201903195T4 (tr) Apiksaban formülasyonları.
MY150855A (en) Oral compositions containing extracts of zizyphus joazeiro and related methods
IN2012DN01233A (de)
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
IN2012DN03182A (de)
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2011011109A (es) Formulaciones orales de bendamustina.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
UA99787C2 (en) Lactams as beta secretase inhibitors
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
TN2010000299A1 (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropy-ran-4-yl)-propionamide
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
MX2010005714A (es) Compuestos de piridina.
IN2012DN01232A (de)
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.